2018
DOI: 10.1002/ppul.23963
|View full text |Cite
|
Sign up to set email alerts
|

Respiratory syncytial virus is an “opportunistic” killer

Abstract: Respiratory syncytial virus (RSV), responsible for more than three million yearly hospitalizations and up to 118 000 deaths in children under 5 years, is the leading pulmonary cause of death for this age group that lacks a licensed vaccine. Ninety‐nine percent of deaths due to the virus occur in developing countries. In‐hospital RSV fatalities affect previously healthy term infants in association with bacterial sepsis, clinically significant pneumothoraxes and, to a lesser extent, comorbid conditions. Communit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
26
0
2

Year Published

2018
2018
2022
2022

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 29 publications
(30 citation statements)
references
References 38 publications
2
26
0
2
Order By: Relevance
“…Vaccines have been licensed against the main causes of death associated with respiratory tract infections such as Haemophilus influenzae type B and Streptococcus pneumoniae and as a consequence RSV has remained one of the leading pulmonary causes of death for which no vaccine is yet available [25]. Lots of pharmaceutical companies are presently working on the development of new monoclonal antibodies and vaccines so that RSV infection could be prevented in the risk categories.…”
Section: Discussionmentioning
confidence: 99%
“…Vaccines have been licensed against the main causes of death associated with respiratory tract infections such as Haemophilus influenzae type B and Streptococcus pneumoniae and as a consequence RSV has remained one of the leading pulmonary causes of death for which no vaccine is yet available [25]. Lots of pharmaceutical companies are presently working on the development of new monoclonal antibodies and vaccines so that RSV infection could be prevented in the risk categories.…”
Section: Discussionmentioning
confidence: 99%
“…The structure knowledge was also at the basis of the development of an effective vaccine antigen against the respiratory syncytial virus (RSV). RSV is one of the main cause of hospital visits during infancy and childhood and it is the leading pulmonary cause of death in children under 5 years lacking a licensed vaccine . The trimeric surface fusion (F) glycoprotein of RSV is the major target for antiviral drug development and it has also been identified as a potential vaccine candidate since it can elicit neutralizing antibodies.…”
Section: Structural Vaccinologymentioning
confidence: 99%
“…RSV infection is associated with bronchiolitis, pneumonia, otitis media, rhinitis and other reactive airway diseases [16]. It has been estimated that there are approximately 33.1 million RSV-related cases worldwide per year in children younger than 5 years, and the mortality was 118,200 [17,18]. Early diagnosis and monitoring of RSV infection play a crucial role in the treatment and management of RSV patients.…”
Section: Introductionmentioning
confidence: 99%